mRNA Cancer Medicines for Every Patient
Teaching the immune system to find cancer and fight it.
Cancer hides from the immune system. ImmunoScript makes mRNA-based immunotherapies that carry two kinds of instructions at once.
Lasting
Builds immune memory that keeps watch long after treatment ends.
Off the shelf
Made in advance and ready the day a patient needs it.
Multiplexed
Eight mRNAs in one therapy take on both of cancer's defenses at once.
Why now
The era of mRNA cancer medicine has begun.
What's missing is an effective off-the-shelf option.
mRNA works at global scale
mRNA medicines can be designed quickly and made for millions.
Personalized mRNA is fighting cancer
Custom-made mRNA treatments are helping patients in clinical trials. But each one is built for a single person, and that takes weeks.
An effective off-the-shelf immunotherapy
A ready-made mRNA immunotherapy for a broad patient population, available as soon as needed. That is the gap ImmunoScript is built to fill.
How it works
Two barriers. One therapy.
Tumors block immune cells at two steps: getting in and recognizing the cancer. Our lead therapy, IS-001, unlocks both.
Pipeline
Starting with pancreatic cancer.
Built to expand to other solid tumors.
IS-001 is our lead therapy targeting pancreatic cancer.
| Program | DiscoveryPreclinicalIND-enablingPhase 1 |
|---|---|
| IS-001Lead indication: pancreatic cancerA multiplexed mRNA therapy combining 5 cytokines and 3 tumor antigens.Stage: Preclinical | |
| IS-002Lead indication: solid tumors (undisclosed)Stage: Discovery |
Results
What IS-001 achieved in preclinical studies.
Tested in aggressive mouse models of pancreatic cancer.
Complete response rate
In half of treated mice, tumors were completely eliminated.
Cancer-free
Complete responders stayed cancer-free for a year, long after treatment stopped.
Immune memory
The immune system learned to recognize the cancer and kept watch, so tumors did not return.
Team
Founded by the scientists behind the science.
Marcus Ruscetti, PhD
Co-Founder & Chief Scientific Advisor
Associate Professor, UMass Chan Medical School.
LinkedInNews
Follow our progress.
Redefining mRNA immunotherapy for solid tumors: lessons from our pancreatic cancer research
Read the article August 2026 · UMass Chan Medical SchoolUMass Chan scientists develop an mRNA immunotherapy that clears pancreatic tumors in mice
Read the article May 2026 · UMass Chan Medical SchoolCo-founder Marcus Ruscetti receives the 2026 Pershing Square Sohn Cancer Prize
Read the article October 2024 · Let's Win Pancreatic CancerCo-founder Chaitanya Parikh featured among the next generation of pancreatic cancer researchers
Read the articleOur research is making headlines around the world.
Publications
Peer-reviewed science.
Multiplexed cytokine and antigen mRNA administration generates durable anti-tumor immunity against pancreatic cancer
Read in Nature CommunicationsInvestors & partners
Let's talk about IS-001.
If you're interested in investing in or partnering on the next generation of cancer immunotherapy, send us a note. We read every message and reply personally.
We are also in early discussions to identify potential clinical trial sites. If you're a physician interested in IS-001, we'd be glad to hear from you.
Careers
We're always looking for exceptional people.
Across science, regulatory and business development. If you want to help build the next generation of cancer medicines, we'd love to hear from you.
Get in touch